Achieve Life Sciences (ACHV – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Justin Walsh from JonesTrading reiterated a Buy rating on the stock and has a $20.00 price target.
Protect Your Portfolio Against Market Uncertainty
- Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
- Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
Justin Walsh’s rating is based on Achieve Life Sciences’ progress with their lead product, cytisinicline, which is on track for a New Drug Application (NDA) submission in June 2025. The company’s interactions with the FDA have been smooth, with no disruptions due to leadership changes, and they have met the FDA’s requirement for long-term safety data. The Data Safety Monitoring Committee’s independent review found no safety concerns, which adds confidence to the product’s safety profile.
Moreover, Achieve Life Sciences is preparing a robust digital commercialization strategy in collaboration with Omicom, which positions cytisinicline well for market entry if approved. Cytisinicline’s potential to become the first FDA-approved nicotine addiction treatment in nearly two decades, coupled with its favorable odds ratio and lower adverse event rates compared to previous treatments like CHANTIX, further supports the Buy rating. The company’s strategic planning and promising clinical data underpin the positive outlook for Achieve Life Sciences’ stock.
Walsh covers the Healthcare sector, focusing on stocks such as Achieve Life Sciences, Actinium Pharmaceuticals, and Serina Therapeutics. According to TipRanks, Walsh has an average return of -6.7% and a 25.63% success rate on recommended stocks.